Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion

Other illness

• Hypothermia-specific contraindications： (1)Hypothermia: Baseline core body temperature (rectal) \<36.0°C; (2)History of cryoglobulinemia, sickle cell anemia, or Raynaud's disease;
• Life expectancy \<90 days (due to other fatal diseases); 4.Currently participating in other clinical trials; in the research or follow-up phase.

Lab values

• High-risk cardiac factors:
  • (1)Sick sinus syndrome (SSS); (2)Second-degree type II or third-degree atrioventricular block (without pacemaker implantation); (3)Baseline heart rate \<50 bpm or QTc \>500 ms; (4)History of severe heart failure (LVEF \<30%); 3.Severe clinical status:

Other

• Refractory shock: admission systolic blood pressure \<90 mmHg requiring combined or high-dose vasopressors for maintenance;
• Pregnant or lactating women;

• Age ≥ 18 years;
• Sudden onset of focal or global neurological deficit symptoms;
• Emergency imaging (CTA, MRA, or DSA) prior to randomization confirms occlusion of the basilar artery or vertebral artery. In the case of vertebral artery occlusion, bidirectional blood flow to the basilar artery must be completely obstructed, accompanied by corresponding neurological deficit symptoms;
• EVT is initiated within 24 hours of symptom onset;
• The National Institutes of Health Stroke Scale (NIHSS) score is ≥10 before the start of the procedure;
• Pc-ASPECTS ≥3;
• Pre-stroke mRS score of 0-1;
• Randomization Trigger Conditions:
  • (1)Successful recanalization of the basilar artery after endovascular treatment; (2)Definition of successful recanalization: eTICI grade reaching 2b, 2c,or 3; 9.The patient or their legal guardian is able to understand the purpose of the trial, voluntarily participate and sign a written informed consent form, and is capable of undergoing clinical follow-up.